eXoZymes, Inc.
EXOZHealthcareNASDAQBiotechnology · Last scanned Oct 22, 2026
Scan Results
Daily timeframePart of the healthcare sector, eXoZymes, Inc. (EXOZ) is listed under Biotechnology. At a $36.5M market cap, eXoZymes, Inc. ranks as a micro-cap company within healthcare. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing.
Market Cap
$36.5M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.13
EPS (Fwd)
—
ROE
-187.2%
ROA
-74.7%
Cash
$5.7M
Total Debt
$1.1M
Free CF
-$3.3M
52W Change
-66.4%
Annual Financials
Cash vs Debt
Where EXOZ stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, EXOZ finished 46.74% below its 150-day moving average ($7.51) and 50.25% below its 200-day moving average ($8.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EXOZ overbought or oversold?
At the October 20, 2026 close, EXOZ's RSI(14) was 5.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $5.7M in cash and $1.1M in debt, EXOZ maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$3.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -187.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for eXoZymes, Inc. and its sector.